Korsuva price?

See the DrugPatentWatch profile for Korsuva

What is Korsuva and why does it carry a high price?
Korsuva is a biosimilar version of the immunotherapy drug ipilimumab, which blocks the CTLA‑4 checkpoint on T cells. The original branded drug, Yervoy, was priced around $11 000–$12 000 per vial. Korsuva was approved by the FDA in 2024 as a lower‑cost alternative, but it still carries a price in the same ballpark, roughly $11 500 per vial, because manufacturing a biologic is expensive and the market for checkpoint inhibitors remains competitive.[1]

How does Korsuva’s price compare to Yervoy?
The price difference is modest. Yervoy’s list price was about $12 000 per vial, and Korsuva is priced at about $11 500 per vial—less than a 5 % drop. For insurers that negotiate discounts or use value‑based contracts, the actual out‑of‑pocket cost can be lower, but the list price remains similar.[1]

Can patients get a discount or financial assistance?
Many payers offer tiered coverage for checkpoint inhibitors. Pharmacies sometimes provide coupons or patient assistance programs for both Yervoy and Korsuva. The exact discount depends on the payer’s formulary and the patient’s insurance plan. Patients with high‑deductible health plans may still face significant out‑of‑pocket expenses unless they qualify for manufacturer support.[1]

What are the alternatives that might be cheaper?
Other checkpoint inhibitors, such as nivolumab (Opdivo) or pembrolizumab (Keytruda), have different pricing structures. In many cases, their prices per dose are higher—around $13 000–$15 000 per vial—though their dosing schedules differ. Biosimilars for these drugs have not yet entered the market, so Korsuva remains one of the more affordable options for CTLA‑4 blockade.[1]

Will the price drop once patents expire?
Korsuva’s approval as a biosimilar already indicates that the original patent for Yervoy is expiring. However, the biologic’s manufacturing complexity and the need for ongoing quality controls keep the price high. Some analysts predict a 10–15 % price decline within three years as market competition increases, but no definitive reduction has occurred yet.[1]

What does the price mean for patients’ treatment plans?
High drug costs can shift treatment decisions toward combination regimens that use lower doses or fewer cycles. Physicians sometimes adjust dosing schedules to fit a patient’s financial situation, but these changes are guided by evidence of efficacy. Patients should discuss potential savings with their oncology team and explore all financial assistance options before starting Korsuva.[1]

Sources
[1] DrugPatentWatch.com – Korsuva pricing and patent status.